Subscribe to RSS
DOI: 10.1055/s-0031-1297172
Testing for Lipoprotein(a) Concentration and Apolipoprotein(a) Phenotypes: Method Standardization and Pediatric Reference Values
Publication History
Publication Date:
20 December 2011 (online)

ABSTRACT
Increased levels of lipoprotein(a) (Lp[a])are known independent risk factor for atherosclerosis, heart disease, and stroke in adults. Even in children it could be shown that elevated levels of Lp(a) are an independent risk factor for symptomatic thromboembolism. The aim of this work was to describe the methods used for evaluating Lp(a) phenotypes, to link them to Lp(a) plasma concentrations, and to establish age-dependent reference values in children. Lp(a) plasma concentrations were measured with enzyme-linked immunosorbent assay technique in parallel to agarose gel electrophoresis and subsequent anti-apolipoprotein(a) immunoblotting. We included 184 pediatric patients with stroke or venous thromboembolism, and 150 healthy age-matched controls in this study. In the control children we could find a mean Lp(a) concentration of 3 mg/dL for children 1 to 12 months of age, and in subjects 1.2 to 18 years of age, the mean Lp(a) concentration was 10 mg/dL. Using percentile classification the upper percentile cut-offs were as follows: age 3 to 6 months: 14 mg/dL; 6.1 to 12 months: 15 mg/dL; 1.1 to 9 years: 22 mg/dL; and 9.1 to 18 years: 30 mg/dL, respectively. In the present study we have established age-dependent reference values of plasma Lp(a) concentrations. The latter will help to harmonize international pediatric studies and to further evaluate the role of elevated Lp(a) in childhood vascular disease.
KEYWORDS
Apolipoprotein(a) - phenotyping - isoelectric focusing - immunoblotting technique - reference values
REFERENCES
- 1 Kostner G M. Lipoprotein(a): metabolismus und beeinflussung des plasmaspiegels. Austrian J Cardiol. 2002; 9 321-324
- 2 Nowak-Göttl U, Junker R, Hartmeier M et al.. Increased lipoprotein(a) is an important risk factor for venous thromboembolism in childhood. Circulation. 1999; 100 (7) 743-748
- 3 Marcovina S M, Hobbs H H, Albers J J. Relation between number of apolipoprotein(a) kringle 4 repeats and mobility of isoforms in agarose gel: basis for a standardized isoform nomenclature. Clin Chem. 1996; 42 (3) 436-439
- 4 Nowak-Göttl U, Langer C, Bergs S, Thedieck S, Sträter R, Stoll M. Genetics of hemostasis: differential effects of heritability and household components influencing lipid concentrations and clotting factor levels in 282 pediatric stroke families. Environ Health Perspect. 2008; 116 (6) 839-843
- 5 Utermann G. The mysteries of lipoprotein(a). Science. 1989; 246 (4932) 904-910
- 6 Boerwinkle E, Leffert C C, Lin J, Lackner C, Chiesa G, Hobbs H H. Apolipoprotein(a) gene accounts for greater than 90% of the variation in plasma lipoprotein(a) concentrations. J Clin Invest. 1992; 90 (1) 52-60
- 7 Sträter R, Becker S, von Eckardstein A et al.. Prospective assessment of risk factors for recurrent stroke during childhood—a 5-year follow-up study. Lancet. 2002; 360 (9345) 1540-1545
- 8 Middelberg RPS, Spector T D, Swaminathan R, Snieder H. Genetic and environmental influences on lipids, lipoproteins, and apolipoproteins: effects of menopause. Arterioscler Thromb Vasc Biol. 2002; 22 (7) 1142-1147
Ulrike Nowak-GöttlM.D.
Professor, Thrombosis & Hemostasis Unit, Center of Clinical Chemistry, University Hospital Schleswig-Holstein
Campus Kiel, Arnold-Heller-Str. 3, 24105 Kiel, Germany
Email: leagottl@uk-sh.de